JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohmori, Y.
Right arrow Articles by Hamilton, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohmori, Y.
Right arrow Articles by Hamilton, T. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 44, 29202-29209, October 30, 1998


STAT6 Is Required for the Anti-inflammatory Activity of Interleukin-4 in Mouse Peritoneal Macrophages*

Yoshihiro OhmoriDagger and Thomas A. Hamilton

From the Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Interleukin-4 (IL-4) is an anti-inflammatory cytokine which inhibits many inducible macrophage functions. The present study demonstrates that the ability of IL-4 to inhibit interferon gamma (IFNgamma )-dependent gene transcription is dependent upon STAT6. IL-4 suppressed IFNgamma -induced expression of the MIG (monokine induced by IFNgamma ) gene, a C-X-C chemokine, in mouse macrophages. IFNgamma -induced expression of MIG mRNA was abolished in peritoneal macrophages from Stat1-/- mice, and the suppression of MIG mRNA by IL-4 was abolished in macrophages from Stat6-/- mice. Transient transfection assays using a reporter gene containing the MIG gene promoter or the IFNgamma -responsive element (gamma RE) from the MIG gene revealed that the IFNgamma -dependent transcription was suppressed by IL-4, although IL-4 alone had no transactivating function. IFNgamma and IL-4 activated STAT1 and STAT6, respectively, and both proteins were able to bind the gamma RE motif. Furthermore, STAT6 was associated with the co-activator CREB-binding protein in RAW264.7 cells. These observations indicate that STAT6 is necessary for the IL-4-mediated suppression of IFNgamma -induced, STAT1-dependent transcription and suggest that STAT6 may directly suppress the STAT1-dependent transcription by competing with STAT1 for occupancy of the gamma RE motif and/or by competing with limiting quantities of the transcriptional coactivator.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Regulation of inflammatory and immune responses involves intercellular communication through a network of secreted cytokines (1). Cytokines derived from T helper (Th)1 1 cells (prototypically IFNgamma ) promote the development of cellular immunity, while Th2-derived cytokines such as IL-4 promote humoral immunity and antagonize Th1-dependent activities (2-5). At least a portion of the anti-inflammatory function of IL-4 is targeted to mononuclear phagocytes where expression of inducible genes encoding cytokines (e.g. TNFalpha , IL-1alpha , IL-1beta , various chemokines) (6-16) and cell surface molecules (FcRgamma and ICAM-1) (17, 18) is suppressed, while expression of other anti-inflammatory products such as the IL-1 receptor antagonist is amplified (9-11, 19, 20).

The molecular mechanisms mediating cytokine-induced gene transcription have been extensively characterized in recent studies on the Janus kinase (JAK) family of protein tyrosine kinases and signal transducers and activators of transcription (STATs) (21-25). IFNgamma has been shown to induce phosphorylation of STAT1, which, in homodimeric form, binds to the IFNgamma activation sequence (GAS) found in many IFNgamma -inducible genes (26-29). In similar fashion, IL-4 stimulates tyrosine phosphorylation of STAT6 (30-32), which can bind to GAS motifs as well as IL-4-responsive STAT binding elements (SBEs) found in IL-4-inducible genes (20, 33-37). Interestingly, STAT6 exhibits transactivating function only in the context of a subset of SBE sequence motifs (20, 34, 37-40).

IL-4 and IFNgamma exhibit antagonistic effects on macrophage gene expression (14-18). We have previously observed that IFNgamma -mediated induction and IL-4-mediated suppression utilize the same regulatory sequences (the ISRE in the IP-10 gene and the GAS motif in the IRF-1 gene) (16, 40). Furthermore, IL-4 does not inhibit the activation of STAT1 by IFNgamma and IL-4-induced STAT6 is able to bind the IFNgamma -responsive site without transactivation (40). Recent studies have shown that STAT1-dependent transcription requires transcriptional coactivators p300 and CREB-binding protein (CBP), which may be present in limiting amounts (41, 42). On the basis of these lines of evidence, we postulated that the inhibitory effect of IL-4 may result, at least in part, from the direct action of IL-4-induced STAT6 on IFNgamma -induced STAT1-dependent transcription. The present study was undertaken to determine if IL-4-induced STAT6 is required for the suppressive action of IL-4 on IFNgamma -induced gene transcription and to extend our analysis to include the IFNgamma -responsive element (gamma RE), which controls expression of the MIG chemokine gene (43, 44), a third form of IFNgamma -sensitive nucleotide regulatory motif. The results demonstrate that IL-4-dependent suppression of IFNgamma -induced MIG gene expression is abolished in peritoneal macrophages from mice in which the STAT6 gene has been deleted (45). Both the MIG gene promoter and the gamma RE from the MIG promoter are sensitive to the stimulatory action of IFNgamma and the inhibitory effects of IL-4. Furthermore, we find that STAT6 as well as STAT1 can interact with the coactivator CBP. These results suggest that these two factors may compete for coactivator and/or occupancy of the gamma RE site with opposite functional consequences.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Reagents and Antibodies-- Recombinant mouse IFNgamma and IL-4 were obtained from Life Technologies, Inc. and R & D Systems, Inc. (Minneapolis, MN), respectively. Rabbit polyclonal antibodies to mouse STAT1alpha (M-23), STAT6 (M-20), CBP (C-20), NFkappa B1(NLS), and RelA (A) were obtained from Santa Cruz Biotechnology (Hercules, CA). Normal rabbit IgG was obtained from Sigma.

Mice-- Homozygous STAT1 mutant mice (Stat1-/-) in which the Stat1 gene has been deleted by homologous recombination were kindly provided by Dr. Robert D. Schreiber (Washington University School of Medicine, St. Louis, MO) (46). Stat6-/- mice were kindly provided by Dr. James N. Ihle (St. Jude Children's Research Hospital, Memphis, TN) (45). Specific pathogen-free C57Bl/6 mice 9-12 weeks of age were purchased from the Trudeau Institute (Saranac Lake, NY).

Cell Culture-- Thioglycollate-elicited peritoneal macrophages were prepared as described previously (47) and cultured in RPMI 1640 containing L-glutamine, penicillin, streptomycin, and 5% fetal bovine serum. The RAW264.7 or ANA-1 (48) mouse macrophage-like cell lines were cultured in Dulbecco's modified Eagle's medium containing L-glutamine, penicillin-streptomycin, and 10% fetal bovine serum.

Preparation of RNA and Northern Hybridization Analysis-- Total cellular RNA was extracted by the guanidine isothiocyanate-cesium chloride method (49). Northern hybridization analysis and cDNA probes for mouse MIG and rat GAPDH were described previously (47, 50). Northern blots were also quantified using phosphorescence detection. The relative magnitude of expression was determined for each gene and normalized to values for GAPDH expression in the same experiment.

Nuclear Run-on Assay-- Cultures of 6 × 107 RAW264.7 cells in 150-mm Petri dishes were treated as indicated in the text for 90 min, and nuclei were isolated as described previously (51). Transcription initiated in intact cells was allowed to complete in the presence of [alpha -32P]UTP (NEN Life Science Products), and the RNA was isolated and hybridized to slot-blotted plasmid containing specific cDNA insert (7 µg of DNA/slot) as described elsewhere (52).

Reporter Plasmids-- A sequence encoding the 5'-flanking promoter/enhancer region of the MIG gene was cloned by PCR using Ultima DNA polymerase (Perkin-Elmer) from a mouse genomic DNA using a set of primers corresponding to the mouse MIG genomic sequence (53) (upstream primer; 5'-TCGCCATATAGTGTCATGTCCC-3', downstream primer; 5'-CTGTGTTGGAGTGAAGTCCG-3'). The amplified PCR fragment was subcloned into luciferase reporter construct (pGL2-B, Promega) and the nucleotide sequence confirmed. The sequences corresponded to nucleotide residues -328 through +34 (53). The 5'-half-site of the gamma RE motif at position -198 to -189 of the MIG promoter was mutated by using two-step PCR amplification (54). The mutant sequence utilized was TCCCggAggATccACT. Lowercase letters represent the mutant sequence, and the underlined sequence is the 5'-half-site of the gamma RE. One copy of the gamma RE motif (sense strand: 5'-gATCCCTTACTATAAACTCCCCGTTTATGTGAAATGGA-3') was placed in front of a heterologous thymidine kinase promoter (55) linked to the luciferase gene (pTK-81Luc). The luciferase control plasmid under control of the cytomegalovirus promoter was provided by Dr. G. Sen (Dept. of Molecular Biology, Cleveland Clinic Foundation).

Transient Transfection-- Luciferase reporter gene plasmids were transiently transfected into RAW264.7 cells by the DEAE-dextran method as described previously (20, 56). Briefly, 15 µg of reporter plasmid DNA and 3 µg of reference plasmid (pRL-TK, Promega) were transfected in the presence of DEAE-dextran (300 µg/ml). To standardize transfection efficiencies, the transfected cells were harvested, pooled, and seeded in four 60-mm culture dishes. After 24 h, the cells were stimulated with IFNgamma and/or IL-4 for 8 h prior to analysis of luciferase activity. Firefly and Renilla luciferase activities were assayed using reagents provided by Promega according to the manufacturer's instructions. Twenty µg of extract protein were utilized in each assay.

Immunoprecipitation and Western Blot Analysis-- Cultures of 6 × 107 RAW264.7 cells in 150-mm Petri dishes were treated as indicated in the text. After stimulation, RAW264.7 cells were washed with ice-cold phosphate-buffered saline, harvested, and resuspended in Lysis buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM Na3VO4, and 10 µg/ml leupeptin, antipain, aprotinin, and pepstatin) for 10 min on ice. After pre-clearing the lysate with normal rabbit IgG (Sigma) and Protein G-Sepharose (Amersham Pharmacia Biotech), whole cell lysate (~500 µg of protein) were incubated with anti-CBP (1 µg) or normal rabbit IgG and protein G-Sepharose (50% slurry) for 16 h at 4 °C. The immunoprecipitates were washed six times with 1 ml of lysis buffer, eluted with SDS-PAGE sample buffer, resolved on 7.5% SDS-PAGE, and analyzed by Western blot as descried previously (40).

Electrophoretic Mobility Shift Assay (EMSA)-- Nuclear extracts were prepared as described previously using a modified method of Dignam et al. (20, 40, 57). The following oligonucleotides were used in EMSA: gamma RE: 5'-GATCCCTTACTATAAACTCCCCGTTTATGTGAAATGGA-3'; mut5'gamma RE: 5'-GATCCCggAggATccACTCCCCGTTTATGTGAAATGGA-3'; 5'-half-site: 5'-ATCCCTTACTATAAACTCCC-3'; 3'-half-site: 5'-CCCCGTTTATGTGAAATGGA-3.

For binding reactions, nuclear extracts (5 µg of protein) were incubated in 12.5 µl of total volume containing 20 mM HEPES (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 5% glycerol, 200 µg/ml bovine serum albumin, and 1.25 µg of poly(dI-dC) for 15 min at room temperature. 32P-Labeled oligonucleotide (0.5 ng, 5 × 105 cpm) was then added to the reaction mixture and incubated for 15 min at room temperature. The reaction products were analyzed by electrophoresis in a 5% polyacrylamide gel with 0.25× TBE buffer (22.3 mM Tris, 22.2 mM borate, 0.5 mM EDTA). In some experiments, rabbit antibody to NFkappa B1 (p50), RelA (p65), STAT1, and STAT6 were added prior to electrophoresis. The dried gels were analyzed by autoradiography and by phosphorescence detection.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

IL-4 Suppresses IFNgamma -induced Expression of MIG mRNA-- IL-4 is known to suppress IFNgamma -induced gene expression in mononuclear phagocytes (14-18). The MIG gene encodes a C-X-C Chemokine known to be transcriptionally regulated by IFNgamma (43, 44, 53). To determine whether IL-4 can suppress MIG expression, thioglycollate-elicited peritoneal macrophages were pretreated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with different doses of IFNgamma for 4 h prior to preparation of total RNA and Northern hybridization analysis. IFNgamma induced and IL-4 suppressed levels of MIG mRNA (Fig. 1A). IL-4 did not alter the kinetics of IFNgamma -induced MIG mRNA expression but reduced the steady state mRNA levels over the entire time course (Fig. 1B). Quantitatively and qualitatively similar effects of IFNgamma and IL-4 on MIG mRNA were seen in the macrophage-like cell lines RAW264.7 (Fig. 1C) and ANA-1 (Fig. 1D). The suppression by IL-4 was mediated predominantly by inhibiting transcription as assessed by nuclear run-on assay in RAW264.7 cells (Fig. 2).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   IL-4 suppresses IFNgamma -induced MIG mRNA expression in macrophages. A, thioglycollate broth-elicited peritoneal macrophages were pretreated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with different concentrations of IFNgamma for 4 h prior to preparation of total RNA and analysis of specific mRNA levels by Northern hybridization as described under "Experimental Procedures." Five µg of total RNA were analyzed in each lane. Similar results were obtained in two separate experiments. B, time dependence of MIG mRNA expression in IFNgamma - and/or IL-4-stimulated macrophages. Thioglycollate broth-elicited peritoneal macrophages were pretreated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with IFNgamma (100 units/ml) for the indicated times prior to analysis of specific mRNA levels as described above. Northern blots were quantified by phosphorimage analysis, and relative mRNA levels are presented as percentage of maximum expression as described under "Experimental Procedures." C and D, RAW264.7 (C) or ANA-1 (D) macrophages were unstimulated or pretreated with IL-4 (10 ng/ml) for 15 min prior to stimulation with increasing concentrations of IFNgamma as indicated for 4 h. Levels of MIG mRNA were determined by Northern hybridization as described above. Similar results were obtained in two separate experiments.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   IL-4 suppresses rate of the IFNgamma -induced MIG transcription. RAW264.7 cells were untreated (UT) or pretreated with IL-4 (10 ng/ml) for 15 min, followed by followed by stimulation with or without IFNgamma (100 units/ml) for 90 min prior to isolate nuclei. Transcription was assessed by nuclear run-on assay as described under "Experimental Procedures." Radiolabeled RNA transcripts were hybridized with slot blotted cDNA encoding MIG or GAPDH as indicated. Similar results were obtained in two separate experiments.

The Effects of IFNgamma and IL-4 on MIG Expression Require STAT1 and STAT6, Respectively-- STAT1 is believed to be important for most if not all IFNgamma -induced gene expression (46, 58), while STAT6 is a primary signaling molecule linked with response to IL-4 (45, 59, 60). To examine the role of IFNgamma -induced STAT1 and IL-4-activated STAT6 in control of MIG expression, macrophages from Stat1-/- and Stat6-/- mice were used to measure each response (45, 46) (Fig. 3). As expected, IFNgamma -induced MIG mRNA expression was completely abolished in peritoneal macrophages from Stat1-/- mice (Fig. 3A) but remained intact in macrophages from Stat6-/- (Fig. 3B). Whereas IFNgamma -induced MIG mRNA was inhibited by IL-4 in wild type macrophages, the suppressive effect of IL-4 was entirely lost in macrophages from the Stat6-/- mice (Fig. 3, B and C).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   STAT6 is indispensable for the IL-4-mediated suppression of the IFNgamma -induced, STAT1-dependent expression of MIG mRNA. A, thioglycollate broth-elicited peritoneal macrophages from wild type mice or from Stat1-/- mice were untreated (UT) or stimulated with IFNgamma (100 units/ml) for 4 h. Levels of murine MIG mRNA were determined by Northern hybridization. Five µg of total RNA were analyzed in each lane. B, thioglycollate broth-elicited peritoneal macrophages from wild type mice or from Stat6-/- mice were untreated (UT) or pretreated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with IFNgamma (100 units/ml) for 4 h prior to analysis of specific mRNA levels by Northern hybridization. Five µg of total RNA were analyzed in each lane. C, Northern blots were quantified by phosphorimage analysis and relative mRNA levels are presented as percentage of the IFNgamma -induced expression. Each column and bar represents the mean ± S.E. from three independent experiments.

The gamma RE Motif in the MIG Promoter Is Sensitive to Both IFNgamma and IL-4-- IFNgamma -induced transcription of the MIG gene has been shown to depend upon the gamma RE motif located at positions -198 to -171 in the MIG promoter (44). To determine whether the suppression of IFNgamma -induced MIG gene expression by IL-4 is dependent upon the gamma RE motif, 328 nt of the 5'-flanking sequence of the MIG gene were linked to the luciferase reporter gene and transiently transfected into RAW264.7 cells. Twenty-four hours after transfection, the cultures were stimulated with IFNgamma alone or in the presence of IL-4 for 8 h prior to analysis of luciferase activity. Although IL-4 alone had no effect on luciferase activity, reporter gene expression was markedly elevated in cells stimulated with IFNgamma (Fig. 4A). IL-4 added along with IFNgamma suppressed the induced luciferase activity by approximately 50%. IL-4 did not modulate the luciferase activity from the cells transfected with cytomegalovirus promoter-driven luciferase construct (data not shown).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of IFNgamma and IL-4 on transcription from the MIG promoter. A, the luciferase reporter construct (shown schematically) was transiently transfected into RAW264.7 cells as described under "Experimental Procedures." Twenty-four h after transfection, the cells were pretreated with IL-4 (10 ng/ml) for 15 min prior to stimulation with IFNgamma (100 units/ml) for 8 h, followed by analysis of cell extracts for luciferase activity. The relative luciferase activity is presented as a percentage of activity obtained in cells stimulated with IFNgamma (100 units/ml) alone. Each column and bar represents the mean ± S.E. from three independent experiments. B, RAW264.7 cells were transiently transfected with a luciferase reporter plasmid containing one copy of the MIG gamma RE motif linked to the TK promoter (TK-81) as shown schematically. After 24 h, the cells were either unstimulated (UT) or treated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with IFNgamma (100 units/ml) for 8 h prior to measurement of luciferase activity. The relative luciferase activity is presented as percentage of maximum activity obtained in cells transfected with the reporter plasmid stimulated with IFNgamma (100 units/ml). Each column and bar represents the mean ± S.E. from three independent experiments. The -fold induction of stimulated versus unstimulated samples is also indicated over the column.

To determine if the gamma RE motif of the MIG gene was the target site for IL-4, one copy of this motif was placed in front of the TK promoter (TK-81) linked to the luciferase reporter gene and transiently transfected in RAW264.7 cells (Fig. 4B). As was observed for the natural MIG promoter, IFNgamma stimulated luciferase expression. IL-4 alone had no effect but suppressed the response to IFNgamma by approximately 50%. Luciferase activity from TK-81 alone was not affected by IFNgamma and/or IL-4 (data not shown).

IL-4-induced STAT6 Interacts with Coactivator CBP-- The promoter analysis of the MIG gene indicates that the gamma RE motif is essential for both the IFNgamma -induced transcriptional activation of the MIG promoter and the suppressive effect of IL-4. Furthermore, STAT6 is required for the suppressive activity of IL-4. Since STAT1-dependent transcription has been demonstrated to require the presence of the coactivator p300 or CBP (41, 42), it is conceivable that suppression might involve competition between STAT1 and STAT6 for limiting quantities of the coactivator. To explore this possibility, we assessed whether STAT6 can interact with CBP in vivo using a co-immunoprecipitation analysis (Fig. 5). Consistent with previous results (41, 42), STAT1 was present in immunoprecipitates using antibody to CBP in whole cell lysates from RAW264.7 cells, and the association appeared to be independent of stimulation (Fig. 5A). The same CBP immunoprecipitates also contained STAT6 (Fig. 5B). These results indicate that STAT6 as well as STAT1 binds CBP and are consistent with the possibility that STAT6 may compete for coactivator CBP.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Association of STAT1 and STAT6 with CBP in RAW267.4 cells. Whole cell extracts were prepared from RAW264.7 cells either untreated (UT) or pretreated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with or without IFNgamma (100 units/ml) for 30 min before lysis the cells. Whole cell extracts (~500 µg of protein) were immunoprecipitated (IP) with anti-CBP antibody or normal rabbit IgG as indicated. CBP-associated proteins were then eluted, and half of the eluted protein was individually separated by 7.5% SDS-PAGE. One µg of whole cell extract was also loaded onto the gel (Input). Proteins were transferred to membrane and each blots were developed with anti-STAT1alpha (A) and anti-STAT6 (B) antibodies, respectively. The blot in A was subsequently stripped and immunoblotted with anti-CBP antibody (C). Similar results were obtained in two separate experiments.

IL-4-induced STAT6 Binds to the gamma RE Motif-- An alternative possibility is that IL-4-induced STAT6 might compete for binding of STAT1 to the gamma RE motif. Since STAT6 can bind to a number of sequence motifs without transactivating function (20, 38, 40), the occupancy of the gamma RE site by STAT6 might result in suppression and not transactivation. Indeed, although IFNgamma could stimulate reporter gene expression from constructs containing the gamma RE linked to the TK promoter, treatment with IL-4 was entirely inactive. To further test this hypothesis, we determined the ability of STAT1 or STAT6 to bind with the gamma RE motif. Nuclear extracts were prepared from untreated, IFNgamma -treated, and/or IL-4-treated RAW264.7 cells and analyzed by EMSA using a radiolabeled oligonucleotide corresponding to the gamma RE motif (Fig. 6A). Several constitutive gamma RE binding activities were detected in nuclear extracts from untreated cells (designated as I and II). IFNgamma induced two additional gamma RE binding activities (lane 2, a low and a high mobility complex designated as gamma RF-1 and gamma RF-2, respectively). Interestingly, IL-4 induced a single binding complex on the gamma RE motif (lane 3). When the cells were co-stimulated with IFNgamma and IL-4, the pattern of complex formation was essentially the same as seen in nuclear extracts from the cells treated with individual stimuli. As reported previously, IL-4 did not effect the tyrosine phosphorylation or nuclear localization of STAT1 in response to IFNgamma or vice versa (40).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   IFNgamma and IL-4 stimulate different gamma RE binding activities in RAW264.7 cells. A, nuclear extracts were prepared from RAW264.7 cells either untreated (UT) or pretreated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with or without IFNgamma (100 units/ml) for 30 min prior to the preparation of nuclear extracts. Five µg of nuclear extract protein were utilized for assay of DNA binding activities by EMSA using radiolabeled oligonucleotides containing the gamma RE element from the MIG gene. Constitutive binding activities (designated as I and II) and IFNgamma - and IL-4-induced binding activities are indicated as filled and open arrows, respectively. Nonspecific binding activity is designated as ns. B, IL-4-induced gamma RE binding complex contains STAT6. Five µg of nuclear extract protein prepared from RAW264.7 cells were utilized in each reaction with or without addition of antibody (1 µg) to STAT1, STAT6, NFkappa B1, or RelA and assayed for DNA binding activity as described above.

To identify the proteins participating in formation of the gamma RE binding complexes, antibody supershift assays were performed (Fig. 6B). The constitutive binding activities (I and II) in nuclear extracts from untreated cells were reactive with antibodies to NFkappa B1 (p50) and RelA (p65) (lanes 4 and 5). This result is consistent with previous observations of low level of NFkappa B binding activity in nuclear extracts from unstimulated macrophages (61) and that NFkappa B1 (p50) and RelA (p65) recognize and bind to some SBE motifs with low affinity (50, 62). The most slowly migrating constitutive complex represents nonspecific binding since specific competitor could not eliminate the complex (data not shown). When nuclear extracts from IFNgamma -treated cells were analyzed, antibody to STAT1 supershifted the IFNgamma -induced gamma RE binding complexes without affecting NFkappa B1 and RelA (lane 7). A combination of antibodies to STAT1 and NFkappa B1 supershifted the inducible and constitutive binding complexes (lane 11). When nuclear extracts from IL-4-treated cells were analyzed, antibody to STAT6 supershifted the IL-4-induced complex (lane 15). The residual binding activity in nuclear extracts treated with anti-STAT6 and anti-NFkappa B1 (lane 19) appears to be the supershifted-NFkappa B1 as seen in lanes 4 and 11. These results indicate that both IL-4-induced STAT6 and IFNgamma -induced STAT1 recognize the gamma RE motif. Two different complexes containing STAT1 were identified; the more rapidly migrating complex (gamma RF-2) is likely to be STAT1 homodimers, whereas the more slowly migrating complex (gamma RF-1) could be a tetrameric form of STAT1 (63, 64).

STAT6 Binds to the 3'-Half-site of gamma RE-1 Motif-- The gamma RE motif consists of two GAS-like motifs (Fig. 7D), and both sites have been shown to be required for IFNgamma -induced transcription of the MIG gene (44). To determine whether the binding of IL-4-induced STAT6 to the gamma RE motif also requires both 3'- and 5'-half-sites, the 5'-half-site of the gamma RE motif was mutated and tested for binding activity by EMSA (Fig. 7A). Although the IFNgamma -induced gamma RF-1 binding complex was markedly reduced on the mutant oligonucleotide (lane 6), IL-4-induced STAT6 binding remained intact (lane 7). Interestingly, the IFNgamma -induced high mobility complex (gamma RF-2) substantially increased when the mutant oligonucleotide was used as the probe (lane 6). The IFNgamma -induced transcriptional activity of the gamma RE was almost completely abolished when a luciferase reporter construct containing a mutant 5'-half-site was analyzed by transient transfection (Fig. 7B), indicating that the formation of the gamma RF-1 complex is essential for IFNgamma -induced MIG promoter activity. The residual IFNgamma -induced promoter activity in the mutant luciferase construct was still sensitive to IL-4. To determine if the 3'-half-site of the gamma RE motif alone is sufficient for STAT6 binding, oligonucleotides corresponding to the 3' or the 5'-half-site of the gamma RE motif were independently synthesized and tested for IFNgamma - and IL-4-induced binding activity by EMSA. Consistent with the results shown in Fig. 7A, IL-4-induced STAT6 was able to form a complex on the 3'-half-site (lane 15), while IFNgamma stimulated primarily the formation of the high mobility complex gamma RF-2 (lane 14). Interestingly, when the 5'-half-site was used as probe (lanes 17-20), neither IFNgamma nor IL-4 induced any detectable complex formation. These results indicate that while the 3'-half-site of the gamma RE motif is sufficient for STAT6 binding and for gamma RF-2, formation of gamma RF-1 requires both the 3'- and 5'-half-sites.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 7.   IL-4-induced STAT6 preferentially binds to the 3'-half-site of the gamma RE motif. A, nuclear extracts were prepared from RAW264.7 cells as described in the legend of Fig. 6. Five µg of nuclear extract protein were utilized for assay of DNA binding activities in EMSA using radiolabeled oligonucleotides containing the gamma RE or a gamma RE containing a mutant 5'-half-site (mut 5'gamma RE) as shown schematically in D. B, The gamma RF-1 complex is required for the IFNgamma -induced transcriptional activation of the MIG promoter. RAW264.7 cells were transiently transfected with the wild type promoter (MIG-328) or the mutant construct (mut 5'gamma RE) in which the 5'-half-site of the gamma RE has been mutated as indicated in D. After 24 h, the cells were either unstimulated (UT) or treated with IL-4 (10 ng/ml) for 15 min, followed by stimulation with different concentration of IFNgamma for 8 h prior to measurement of luciferase activity. The relative luciferase activity is presented as percentage of maximum activity obtained in cells transfected with the MIG-328 reporter plasmid and stimulated with IFNgamma (100 units/ml). Each column and bar represents the mean ± S.E. from three independent experiments. The -fold induction of stimulated versus unstimulated samples is also indicated. C, nuclear extracts were analyzed for the DNA binding activities by EMSA using radiolabeled oligonucleotides containing the gamma RE-1 or 3'-half-site or 5'-half-site of the gamma RE motif as indicated. Similar results were obtained in two separate experiments. D, nucleotide sequences of wild type and mutant gamma RE-1 oligonucleotides used in this study. The 3'- and the 5'-half-sites of the gamma RE-1 motif are boxed. Mutated nucleotides in the mutant 5'gamma RE are indicated in lowercase. Consensus sequences for the GAS are shown (M, A or C; K, G or T).

Taken together with the previous observation that the gamma RE is not responsive to IL-4 alone (see Fig. 4), the data from the association of STAT6 with CBP and the gamma RE binding suggest two potential possibilities for the antagonistic functions of STAT6 on IFNgamma -induced STAT1-dependent transcription of the MIG gene. 1) IL-4-induced STAT6 could compete for the limiting amount of coactivator CBP, which is necessary for the STAT1-dependent transcription; and/or 2) STAT6 could reduce the frequency of IFNgamma -induced transcription by competing for occupancy of the gamma RE by STAT1.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The initiation, magnitude, and resolution of immune-mediated inflammation are regulated at least in part through the action of pro- and anti-inflammatory cytokines (1, 2). For example, the Th1-derived cytokine IFNgamma promotes the pro-inflammatory function of macrophages through stimulation of new gene expression, and this is often antagonized by the Th2-derived cytokine IL-4 (2-5). IFNgamma and IL-4 are both known to activate distinct members of the STAT family of transcription factors, each of which may exhibit differential transactivating potential depending upon the sequence motif to which they bind (20, 34, 37-40). In consideration of this, we postulated that the antagonistic action of IL-4 on IFNgamma -stimulated gene transcription is mediated, at least part, through a direct antagonistic action of IL-4-activated STAT6. The results from the present study demonstrate that STAT6 is indispensable for the negative regulatory function of IL-4 on IFNgamma -induced, STAT1-dependent transcription of the MIG gene in mouse macrophages, and both factors appear to mediate their action through the gamma RE motif found in the MIG gene promoter. These conclusions are based on the following observations. 1) IFNgamma -induced MIG mRNA expression was suppressed by IL-4 in primary macrophages and in ANA-1 or RAW264.7 macrophage-like cell lines. 2) IFNgamma -induced MIG gene expression was abolished in peritoneal macrophages from Stat1-/- mice, while the suppressive effect of IL-4 was abolished in macrophages from Stat6-/- mice. 3) IL-4 suppressed the IFNgamma -induced transcription of a luciferase reporter gene linked to either a 328-base pair fragment flanking the transcriptional start site of the MIG gene or to a single copy of the gamma RE motif from the MIG gene in the context of a heterologous promoter; IL-4 alone showed no independent transactivating function on either construct.

Our findings provide support for two possible mechanisms through which STAT6 may function to directly suppress IFNgamma -induced gene expression. One mechanism of STAT6-mediated suppression may involve the participation of transcriptional co-activators such as CBP or p300. It has been reported recently that STAT1-dependent transcription requires either CBP and/or p300 (41, 42). Thus the finding that STAT6 can interact with CBP raises the possibility that STAT6 might sequester limiting quantities of CBP and thereby antagonize the STAT1-dependent transcription (41). The association of both STAT1 and STAT6 with CBP was not altered by stimulation with either IFNgamma or IL-4. Thus, these data do not provide any direct evidence of competition between the two STATs for CBP. Nevertheless, further studies of the functional consequences of STAT6-CBP interaction will be required to determine the physiological significance.

The present results are also consistent with a scenario in which STAT6 and STAT1 compete for occupancy of the gamma RE regulatory site, as has been suggested previously in studies of the effects of IL-4 on IFNgamma -stimulated IRF-1 expression (40). Because STAT6 has poor transactivating function on the MIG promoter, occupancy of the STAT1 binding site by STAT6 would result in reduced transcription. The nature of the regulatory sequence motif that determines both induction and suppression of the MIG gene (gamma RE) provides some unique features to the potential interactions between SBEs and STAT1 or STAT6. First, the formation of the gamma RF-1 complex requires both the 3'- and 5'-half-sites of the gamma RE motif while STAT6 only recognizes the 3'-half-site. Second, the mutant 5'-half-site version of the gamma RE motif will form gamma RF-2 but not gamma RF-1 and is functionally inactive in supporting IFNgamma -driven reporter gene transcription. Thus, the gamma RF-1 complex but not the gamma RF-2 complex is essential for the IFNgamma -induced transcriptional activity of the MIG gene. Finally, IL-4-induced STAT6 is able to bind to the gamma RE (3'-half-site) without transactivating function. These findings suggest that binding of STAT6 on the 3'-half-site may prevent the formation of the gamma RF-1 complex, resulting in decreased transcriptional frequency.

STAT6 exhibits the broadest DNA binding specificity of all STAT family members (20, 33-40). However, binding of STAT6 to IFNgamma -responsive motifs does not lead to transcriptional activation despite the fact that STAT6 can interact with CBP. In contrast, STAT6 functions as a transcriptional activator when bound to a subset of SBEs including those found in the IgE or IL-1 receptor antagonist genes (20, 34). Thus, the nucleotide sequence of the DNA binding site is a critical determinant of the transcriptional activating function of STAT6. This may be an important distinguishing feature of STAT6, which allows both positive and negative effects on gene transcription.

The ability of STAT6 to compete with STAT1 for binding to the gamma RE was not detectable by EMSA (Figs. 6 and 7). This result is, however, not surprising since the oligonucleotide concentration in the reaction is in great excess relative to the concentration of STAT1 or STAT6, a condition under which competition between the protein factors will not occur. Reduction of the oligonucleotide concentration to a level at which competition might occur does not allow detection of the complexes (data not shown). Thus EMSA analysis of gamma RE binding activities using nuclear extracts from macrophages treated with IFNgamma and IL-4 would not be expected show reduced formation of the gamma RF-1 complex.

STAT1 has been shown to exhibit a cooperative binding activity with two or more low affinity SBE motifs, which is mediated by the N-terminal region of the protein (63, 64). Thus, it is likely that the IFNgamma -induced gamma RF-1 complex is a tetrameric form of STAT1. The higher mobility gamma RF-2 complex appears to be a STAT1 homodimer, which binds to the 3'-half-site of the gamma RE motif. Interestingly, STAT6 formed only a single complex despite its ability to bind a relatively wide range of SBE motifs (20, 33-40). Whether STAT6 lacks cooperativity in the N-terminal region or the gamma RE motif is insufficient for the cooperative binding of STAT6 remains to be determined.

Although IL-4-mediated anti-inflammatory function has been found to include both post-transcriptional and translational events (8, 12, 66), the majority of reports have identified transcription as a primary molecular target (8, 14, 16, 40, 67-71). The data in the present study further demonstrate that STAT6 is essential for IL-4-mediated suppression of IFNgamma -induced MIG gene expression. Indeed, we have also observed that IL-4-mediated suppression of IFNgamma -induced IP-10, IRF-1, ICAM-1, and inducible nitric-oxide synthase gene expression are also abolished in peritoneal macrophages from Stat6-/- mice (data not shown). IL-13-mediated suppression of inducible nitric-oxide synthase gene expression has also been shown to depend upon STAT6 (72). This collection of studies indicates that IL-4- or IL-13-induced STAT6 can provide negative regulatory function, which is necessary for the anti-inflammatory cytokine action.

    FOOTNOTES

* This work was supported by United States Public Health Service Grants CA62220 and CA39621.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, NN10, 9500 Euclid Ave., Cleveland, Ohio 44195. Tel.: 216-444-4669; Fax: 216-444-9329.

The abbreviations used are: Th, T helper; STAT, signal transducer and activator of transcription; SBE, STAT binding element; GAS, gamma activation sequence; IFNgamma , interferon gamma ; MIG, monokine induced by IFNgamma ; gamma RE, IFNgamma -responsive element; gamma RF, IFNgamma response factor; IRF-1, interferon regulatory factor-1; EMSA, electrophoretic mobility shift assay; IL, interleukin; CBP, CREB-binding protein; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; TK, thymidine kinase; GAPDH, glycealdehyde-3-phosphate dehydrogenase.
    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Oppenheim, J. J., and Neta, R. (1994) FASEB J. 8, 158-162[Medline] [Order article via Infotrieve]
  2. Street, N. E., and Mosmann, T. R. (1991) FASEB J. 5, 171-177[Abstract]
  3. Abbas, A., Murphy, K. M., and Sher, A. (1996) Nature 383, 787-793[CrossRef][Medline] [Order article via Infotrieve]
  4. Paul, W. E. (1991) Blood 77, 1859-1850[Free Full Text]
  5. Ohmori, Y., and Hamilton, T. A. (1994) Pharmacol. Ther. 63, 235-264[CrossRef][Medline] [Order article via Infotrieve]
  6. Hart, P. H., Vitti, G. F., Burgess, D. R., Whitty, G. A., Piccoli, D. S., and Hamilton, J. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3803-3807[Abstract/Free Full Text]
  7. Essner, R., Rhoades, K., McBride, W. H., Morton, D. L., and Economou, J. S. (1989) J. Immunol. 142, 3857-3861[Abstract]
  8. Donnelly, R. P., Fenton, M. J., Kaufman, J. D., and Gerrard, T. L. (1991) J. Immunol. 146, 3431-3436[Abstract]
  9. Fenton, M. J., Buras, J. A., and Donnelly, R. P. (1992) J. Immunol. 149, 1283-1288[Abstract]
  10. Vannier, E., Miller, L. C., and Dinnarello, C. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4076-4080[Abstract/Free Full Text]
  11. Wong, H. L., Costa, G. L., Lotze, M. T., and Wahl, S. M. (1993) J. Exp. Med. 177, 775-781[Abstract/Free Full Text]
  12. Mijatovic, T., Kruys, V., Caput, D., Defrance, P., and Huez, G. (1997) J. Biol. Chem. 272, 14394-14398[Abstract/Free Full Text]
  13. Standiford, T. J., Strieter, R. M., Chensue, S. W., Westwick, J., Kasahara, K., and Kunkel, S. L. (1990) J. Immunol. 145, 1435-1439[Abstract]
  14. Larner, A. C., Petricoin, E. F., Nakagawa, Y., and Finbloom, D. S. (1993) J. Immunol. 150, 1944-1950[Abstract]
  15. Gautam, S., Tebo, J. M., and Hamilton, T. A. (1992) J. Immunol. 148, 1725-1730[Abstract]
  16. Deng, W., Ohmori, Y., and Hamilton, T. A. (1994) J. Immunol. 153, 2130-2136[Abstract]
  17. Te Velde, A. A., Huijbens, R. J. F., De Vries, J. E., and Figdor, C. G. (1990) J. Immunol. 144, 3046-3051[Abstract]
  18. Renkonen, R., Mattila, P., Majuri, M.-L., Paavonen, T., and Silvennoinen, O. (1992) Scand. J. Immunol. 35, 525-530[CrossRef][Medline] [Order article via Infotrieve]
  19. Orino, E., Sone, S., Nii, A., and Ogura, T. (1992) J. Immunol. 149, 925-931[Abstract]
  20. Ohmori, Y., Smith, M. F., Jr., and Hamilton, T. A. (1996) J. Immunol. 157, 2958-2065
  21. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Science 264, 1415-1421[Abstract/Free Full Text]
  22. Larner, A. C., and Finbloom, D. S. (1995) Biochim. Biophys. Acta 1266, 278-287[Medline] [Order article via Infotrieve]
  23. Ihle, J. N., and Kerr, I. M. (1995) Trends Genet. 11, 69-74[CrossRef][Medline] [Order article via Infotrieve]
  24. Schindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621-651[Medline] [Order article via Infotrieve]
  25. Darnell, J. E., Jr. (1997) Science 277, 1630-1635[Abstract/Free Full Text]
  26. Schindler, C., Shuai, K., Prezioso, V. R., and Darnell, J. E., Jr. (1992) Science 257, 809-813[Abstract/Free Full Text]
  27. Shuai, K., Schindler, C., Prezioso, V. R., and Darnell, J. E., Jr. (1992) Science 258, 2808-1812
  28. Pearse, R. N., Feinman, R., Shuai, K., Darnell, J. E., Jr., and Ravetch, J. V. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4314-4318[Abstract/Free Full Text]
  29. Sims, S. H., Cha, Y., Romine, M. F., Gao, P., Gottlieb, K., and Deisseroth, A. B. (1993) Mol. Cell. Biol. 13, 690-702[Abstract/Free Full Text]
  30. Kotanides, H., and Reich, N. C. (1993) Science 262, 1265-1267[Abstract/Free Full Text]
  31. Schindler, C., Kashleva, H., Pernis, A., Pine, R., and Rothman, P. (1994) EMBO J. 13, 1350-1356[Medline] [Order article via Infotrieve]
  32. Hou, J., Schindler, U., Henzel, W. J., Ho, T. C., Brasseur, M., and McKnight, S. L. (1994) Science 265, 1701-1706[Abstract/Free Full Text]
  33. Kohler, I., and Rieber, E. P. (1993) Eur. J. Immunol. 23, 3066-3071[Medline] [Order article via Infotrieve]
  34. Delphin, S., and Stavnezer, J. (1995) J. Exp. Med. 181, 181-192[Abstract/Free Full Text]
  35. Fenghao, X., Saxon, A., Nguyen, A., Ke, Z., Diaz-Sanchez, D., and Nel, A. (1995) J. Clin. Invest. 96, 907-914
  36. Berton, M. T., and Linehan, L. A. (1995) J. Immunol. 154, 4513-4525[Abstract]
  37. Kotanides, H., and Reich, N. C. (1996) J. Biol. Chem. 271, 25555-25561[Abstract/Free Full Text]
  38. Seidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Jr., Stein, R. B., and Rosen, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3041-3045[Abstract/Free Full Text]
  39. Mikita, T., Campbell, D., Wu, P., Willamson, K., and Schindler, U. (1996) Mol. Cell. Biol. 16, 5811-5820[Abstract]
  40. Ohmori, Y., and Hamilton, T. A. (1997) J. Immunol. 157, 2058-2065[Abstract]
  41. Horvai, A. E., Wu, L., Korzus, E., Brand, G., Kalafus, D., Mullen, T., Rose, D. W., Gosenfeld, M. G., and Glass, C. K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1074-1079[Abstract/Free Full Text]
  42. Zhang, J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M., and Darnell, J. E., Jr. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15092-15096[Abstract/Free Full Text]
  43. Farber, J. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5238-5242[Abstract/Free Full Text]
  44. Wong, P., Severns, C. W., Guyer, N. B., and Wright, T. M. (1994) Mol. Cell. Biol. 14, 914-922[Abstract/Free Full Text]
  45. Shimoda, K., Deursen, J. V., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A. A., Doherty, P. C., Grosveld, G., Paul, W. E., and Ihle, J. N. (1996) Nature 380, 630-633[CrossRef][Medline] [Order article via Infotrieve]
  46. Meraz, M. A, White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., and Schreiber, R. D. (1996) Cell 84, 431-442[CrossRef][Medline] [Order article via Infotrieve]
  47. Ohmori, Y., and Hamilton, T. A. (1994) J. Immunol. 5, 2204-2212
  48. Cox, G. W., Mathieson, B. J., Gandino, L., Blasi, E., Radzioch, D., and Varesio, L. (1989) J. Natl. Cancer Inst. 81, 1492-1503[Abstract/Free Full Text]
  49. Chirgwin, J. J., Przbyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5311[CrossRef][Medline] [Order article via Infotrieve]
  50. Ohmori, Y., Schreiber, R. D., and Hamilton, T. A. (1997) J. Biol. Chem. 272, 14899-14907[Abstract/Free Full Text]
  51. Greenberg, M. E., and Ziff, E. B. (1985) Nature 311, 433-438
  52. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1987) Current Protocols in Molecular Biology, p. 4.10, Wiley Interscience, New York
  53. Wright, T. M., and Farber, J. M. (1991) J. Exp. Med. 173, 417-422[Abstract/Free Full Text]
  54. Gustin, K. E., and Burk, R. D. (1993) BioTechniques 14, 22-24[Medline] [Order article via Infotrieve]
  55. McKnight, S. L., Gavis, E. R., and Kingsbury, R. (1981) Cell 25, 385-398[CrossRef][Medline] [Order article via Infotrieve]
  56. Ohmori, Y., and Hamilton, T. A. (1993) J. Biol. Chem. 268, 6677-6688[Abstract/Free Full Text]
  57. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract/Free Full Text]
  58. Durbin, J. E., Hackenmiller, R., Simon, M. C., and Levy, D. E. (1996) Cell 84, 443-430[CrossRef][Medline] [Order article via Infotrieve]
  59. Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., Nakanishi, K., Yoshida, N., Kishimoto, T., and Akira, S. (1996) Nature 380, 627-630[CrossRef][Medline] [Order article via Infotrieve]
  60. Kaplan, M. H., Schindler, U., Smiley, S. T., and Grusby, M. J. (1996) Immunity 4, 313-319[CrossRef][Medline] [Order article via Infotrieve]
  61. Ohmori, Y., Tebo, J., Nedospasov, S., and Hamilton, T. A. (1994) J. Biol. Chem. 269, 17684-17690[Abstract/Free Full Text]
  62. Deng, W., Ohmori, Y., and Hamilton, T. A. (1996) Cell Immunol. 170, 20-24[CrossRef][Medline] [Order article via Infotrieve]
  63. Xu, X., Sun, Y., and Hoey, T. (1996) Science 273, 794-797[Abstract]
  64. Vinkemeier, U., Cohen, S. L., Moarefi, I., Chait, B. T., Kuryan, J., and Darnell, J. E., Jr. (1996) EMBO J. 15, 5616-5626[Medline] [Order article via Infotrieve]
  65. Deleted in proof
  66. Wang, P., Wu, P., Siegel, M. I., Egan, R. W., and Billah, M. M. (1995) J. Biol. Chem. 270, 9558-9563[Abstract/Free Full Text]
  67. Donnelly, R. P., Crofford, L. J., Freeman, S. F., Buras, J., Remmers, E., Wilder, R. L., and Fenton, M. J. (1993) J. Immunol. 151, 5603-5612[Abstract]
  68. Dokter, W. H. A., Esselink, M. T., Halie, R., and Vellenga, E. (1993) Blood 81, 337-343[Abstract/Free Full Text]
  69. Clarke, C. J. P., Taylor-Fishwick, D. A., Hales, A., Chernajovsky, Y., Sugamura, K., Feldmann, M., and Foxwell, B. M. J. (1995) Eur. J. Immunol. 25, 2961-2966[Medline] [Order article via Infotrieve]
  70. Takeshita, S., Gage, J. R., Kishimoti, T., Vredevoe, D. L., and Martinez-Maza, O. (1996) J. Immunol. 156, 2591-2598[Abstract]
  71. Bennett, B., Cruz, R., Lacson, R. G., and Manning, A. M. (1997) J. Biol. Chem. 272, 10212-10219[Abstract/Free Full Text]
  72. Takeda, K., Kamanaka, M., Tanaka, T., Kishimoto, T., and Akira, S. (1996) J. Immunol. 157, 3220-3222[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.